SELANK 5mg

Selank — Research Overview

Introduction

Selank is a short synthetic heptapeptide designed to emulate functions of tuftsin, a natural IgG‐derived fragment linked to immune and behavioral regulation. In research contexts, Selank has been explored for its potential effects on stress responses, mood‐related behaviors, and immune parameters [2,5].

Structurally, Selank comprises tuftsin at the N‐terminus fused to a Pro‐Gly‐Pro (PGP) tripeptide at the C‐terminus. Incorporation of the PGP motif is theorized to influence physicochemical properties and may facilitate transport across select biological barriers (e.g., blood–brain barrier) via receptor‐mediated or carrier‐assisted mechanisms; secondary structural effects of PGP could further modulate transit and receptor interactions [4,6].

Chemical Characteristics

Form: Lyophilized powder for reconstitution (research use)

Research Applications

1. Neurotrophins and Neuroplasticity (BDNF)

– Experimental work reports increased BDNF mRNA in hippocampus after intranasal Selank, suggesting potential influence on neuroplasticity under stress‐related conditions [1].

2. Serotonin Signaling

– In models with impaired serotonin synthesis, Selank has been reported to alter indices of serotonin metabolism in brain regions involved in mood/anxiety regulation [5].

3. GABAergic System and Gene Expression

– Cell and animal studies show correlated transcriptional changes across GABA‐pathway genes after exposure to Selank or GABA, supporting a potential modulatory action on GABAergic neurotransmission [6,7].

4. Genome Expression and Inflammatory Markers

– Transcriptomic studies (hippocampus and spleen) suggest Selank may affect expression of genes including CX3CR1, implicated in inflammatory processes [8].

5. Enkephalin Signaling and Anxiolytic Comparisons

– In clinical research on generalized anxiety and neurasthenia, Selank’s effects on psychometric outcomes appeared comparable to a benzodiazepine comparator; researchers also noted changes in enkephalin‐related measures consistent with reduced peptide degradation [9,10].

6. Memory and Learning

– In conditioned avoidance paradigms, repeated Selank exposure was associated with fewer errors and more correct responses, consistent with improved task performance [11].

7. Immunomodulation

– Clinical observations in anxiety–asthenic cohorts reported changes in IL‐6 and Th1/Th2 indices after 14‐day Selank exposure, consistent with immunomodulatory activity [12].

8. Alcohol Withdrawal Models

– In rodent models with long‐term ethanol intake, Selank exposure was associated with reduced withdrawal‐related behaviors in social interaction and maze tests [13].

9. Cardiovascular Activity

– Feline experiments reported transient reductions in arterial blood pressure and increased cerebral blood flow shortly after Selank exposure, with minimal effects on heart rate/respiration [14].

10. Weight, Lipids, and Hemostasis Parameters

– In diet‐induced models, investigators reported lower total cholesterol/triglycerides and improvements in hemostasis metrics; body‐weight trajectories differed from controls during observation [15].

Conclusion

Selank is a tuftsin‐derived heptapeptide with a PGP extension that has been investigated across neurobehavioral, neurochemical, immune, and metabolic readouts. Preclinical and early clinical research propose actions involving BDNF expression, serotonergic and GABAergic modulation, gene‐expression shifts relevant to inflammation, and changes in anxiety‐related measures and physiological parameters. Findings remain research‐oriented and non‐clinical in scope [1–15].

Selank (TP-7) — References

• Ashmarin, I. P., Kamensky, A. A., Miasoedov, N. F., Grivennikov, I. A., Levitskaya, N. G., Khavinson, V. K., & Dubrovina, N. I. Immunomodulating and anxiolytic peptides: Development of the heptapeptide Selank. Biological Bulletin. 1997;24(5): 491–495.https://doi.org/10.1007/BF02757504
• Ashmarin, I. P., Kamensky, A. A., Miasoedov, N. F., Grivennikov, I. A., Levitskaya, N. G., Khavinson, V. K. Neuropeptide regulation of the immune system and affective states. Annals of the New York Academy of Sciences. 1998;840: 676–678.https://doi.org/10.1111/j.1749-6632.1998.tb09606.x
• Inozemtsev, A. N., Kamensky, A. A., Miasoedov, N. F., Dubrovina, N. I. The anxiolytic and nootropic effects of selank depend on the functional state of the central nervous system. Bulletin of Experimental Biology and Medicine. 2008;145(2): 229–232.https://doi.org/10.1007/s10517-008-0051-1
• Inozemtsev, A. N., Kamensky, A. A., Miasoedov, N. F., Dubrovina, N. I. Comparative analysis of the effects of selank and classical benzodiazepines on learning and anxiety in rats. Neuroscience and Behavioral Physiology. 2008;38(8): 899–902.https://doi.org/10.1007/s11055-008-9077-4
• Andreeva, L. A., Kozlovskaia, M. M., Miasoedov, N. F., Kamensky, A. A. Effect of selank on the expression of genes involved in the regulation of neurotransmission in the rat brain. Bulletin of Experimental Biology and Medicine. 2010;149(5): 612–615.https://doi.org/10.1007/s10517-010-0998-5
• Andreeva, L. A., Kozlovskaya, M. M., Kamensky, A. A., Miasoedov, N. F. Selank regulates the expression of genes involved in GABAergic neurotransmission. Doklady Biological Sciences. 2012;446: 54–56.https://doi.org/10.1134/S0012496612020020
• Ershov, F. I., Gorbunov, E. A., Miasoedov, N. F., Kozlovskaya, M. M., Kamensky, A. A. Antiviral and immunomodulatory activity of the peptide selank in influenza infection models. International Immunopharmacology. 2009;9(4): 458–464.https://doi.org/10.1016/j.intimp.2008.12.009
• Neznamov, G. G., Teleshova, E. S. Comparative clinical study of the anxiolytic effectiveness of selank and phenazepam. Neuroscience and Behavioral Physiology. 2009;39(2): 143–147.https://doi.org/10.1007/s11055-009-9126-6
• Neznamov, G. G., Teleshova, E. S., & Kozlovskaya, M. M. Clinical evaluation of the anxiolytic and nootropic effects of Selank in patients with anxiety-asthenic disorders. Eksperimental’naia i Klinicheskaia Farmakologiia. 2006;69(2): 65–68. (In Russian with English abstract).PubMed PMID: 16579061
• Kamensky, A. A., Inozemtsev, A. N., Kozlovskaya, M. M., & Miasoedov, N. F. Selank as an anxiolytic and nootropic: mechanisms and clinical perspectives. Neuroscience and Behavioral Physiology. 2013;43(7): 803–810.https://doi.org/10.1007/s11055-013-9832-3

NOTICE OF COMPLIANCE

The mission of BioGenix Peptides™ is to provide researchers with the highest-quality, Ultra-Pure Series™ compounds to help unlock the full potential of this evolving field. With precision, purity, and scientific integrity at the core of our operations, BioGenix Peptides™ is dedicated to supporting responsible exploration and discovery

Products from BioGenix Peptides™ are not intended for human consumption. They are supplied exclusively for in-vitro and pre-clinical research purposes.

By purchasing or using these products, the Customer accepts full responsibility for their handling and use, and agrees to indemnify and hold BioGenix Peptides™ harmless from any claims resulting from misuse.